Currently out of the existing stock ratings of Ritu Baral, 113 are a BUY (89.68%), 12 are a HOLD (9.52%), 1 are a SELL (0.79%).

Ritu Baral

Work Performance Price Targets & Ratings Chart

Analyst Ritu Baral, carries an average stock price target met ratio of 60.97% that have a potential upside of 46.38% achieved within 532 days. Previously, Ritu Baral worked at TD COWEN.

Ritu Baral’s has documented 252 price targets and ratings displayed on 29 stocks. The coverage was on Healthcare, Industrials sectors.

Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 10-Sep-2025.

Wall Street Analyst Ritu Baral

Analyst best performing recommendations are on NGM (NGM BIOPHARMACEUTICALS).
The best stock recommendation documented was for NGM (NGM BIOPHARMACEUTICALS) at 2/27/2024. The price target of $1.55 was fulfilled within 1 day with a profit of $0.08 (4.91%) receiving and performance score of 49.08.

Average potential price target upside

of $74.33 (40.08%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $46.91 (42.54%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $44.15 (152.88%) on GBT (GLOBAL BLOOD THERAPEUTICS).

ACAD ACADIA Pharmaceuticals ALBO Albireo Pharma ALNY Alnylam Pharmaceuticals AMRN Amarin PLC FOLD Amicus Therapeutics ICPT Intercept Pharmaceuticals KRYS Krystal Biotech MNTA Momenta Pharmaceuticals NGM NGM Biopharmaceuticals PTCT PTC Therapeutics SAGE Sage Therapeutic SPRB Spruce Biosciences SRPT Sarepta Therapeutics GBT Global Blood Therapeutics MYOK MyoKardia SPRO Spero Therapeutics APTX Aptinyx TERN Terns Pharmaceuticals INSM Insmed MDGL Madrigal Pharmaceuticals CYTK Cytokinetics MIST Milestone Pharmaceuticals QURE Uniqure NV BLU BELLUS Health RNA Avidity Biosciences ANTX AN2 Therapeutics ALDX Aldeyra The AXON Axon Enterprise ITCI Intracellular Th

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tessa Romero (JPMORGAN)